PROTIER Biotech Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PROTIER Biotech Inc. - overview
Established
2022
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2022, PROTIER Biotech Inc. operates as a biotech company that develops anti-cancer drugs based on the molecular glue development platform by targeting the degradation of cancer proteins. In March 2026, PROTIER Biotech Inc. raised KRW 3.
5 billion in pre-series A funding from new investors Hana Ventures, Korea Investment Accelerator, IBK Venture Investment, Mirae Holdings, and T Investment. Other unspecified investors also participated in this round. The company will use the March 2026 funding to accelerate the entry of its drug candidates into the preclinical stage and advance its pipelines by expanding its scope to include ovarian cancer.
Current Investors
Hana Ventures, Mirae Holdings, T Investment
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.protierbiotech.com/
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.